<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942020000400009</article-id>
<article-id pub-id-type="doi">10.30827/ars.v61i4.15473</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Generalidades sobre las vacunas comercializadas en España: estudio monográfico de la vacuna contra el sarampión]]></article-title>
<article-title xml:lang="en"><![CDATA[Generalities of vaccines marketed in Spain: monographic study of the measles vaccine]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mejías-Padilla]]></surname>
<given-names><![CDATA[Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ginés-Dorado]]></surname>
<given-names><![CDATA[Juan Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Sevilla Facultad de Farmacia Departamento de Farmacia y Tecnología Farmacéutica]]></institution>
<addr-line><![CDATA[Sevilla ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>61</volume>
<numero>4</numero>
<fpage>259</fpage>
<lpage>265</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942020000400009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942020000400009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942020000400009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: la vacunación es, en la historia de la medicina, una de las actuaciones más significativas en la reducción de la mortalidad infantil y la erradicación de enfermedades. Sin embargo, con el apogeo de los denominados grupos &#8220;antivacunas&#8221; ha aumentado la incidencia de enfermedades infecciosas, entre ellas, el sarampión, cuya erradicación no ha sido posible para el año 2015, como había propuesto la Organización Mundial de la Salud.  Objetivo: hemos estudiado diferentes aspectos tecnológicos de las vacunas comercializadas en España, centrándonos en las utilizadas contra el sarampión, y su problemática actual a la hora de su administración.  Método: se ha realizado un estudio de las fichas técnicas de las vacunas recogidas en la Agencia Española de Medicamentos y Productos Sanitarios.  Resultados: se obtuvieron resultados sobre diferentes aspectos: tipo de vacuna, sistema fisicoquímico, forma farmacéutica, vía de administración y dispositivo para su administración. Además, se han analizado las formulaciones de las vacunas existentes contra el sarampión, haciendo hincapié en los diversos excipientes que contienen: estabilizadores, antibióticos, medios de cultivo, etc.  Conclusiones: la mayoría de las vacunas comercializadas en España se presentan en forma de suspensión para administración intramuscular o subcutánea mediante jeringa precargada. En el caso de la vacuna contra el sarampión, encontramos tres medicamentos de preparación extemporánea, que se presentan en forma de polvo liofilizado en vial y vehículo en jeringa precargada, producidas a partir de diferentes virus vivos o atenuados, siendo por tanto vacunas combinadas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: in the history of medicine, vaccination is one of the most important operations in the reduction of infant mortality and the eradication of diseases. However, with the apogee of the so-called &#8220;anti-vaccine&#8221; groups has increased the incidence of infectious diseases, including measles, whose eradication is not possible by the year 2015, as the World Health Organization had proposed.  Objective: we have studied different vaccines existing in the Spanish market available to health professionals and we have analyzed the formulations of existing measles vaccines.  Method: the data sheets of different vaccines available to health professionals collected at the Spanish Agency of Medicines and Health Products has been studied.  Results: the results have been obtained from different aspects: type of vaccine, physicochemical system, pharmaceutical form, way of administration or device for its administration. In addition, we have analyzed formulations of existing measles vaccines, by emphasizing different excipients which contain: stabilizers, antibiotics, culture media, etc.  Conclusions: the majority of vaccines marketed in Spain are suspensions, to be administered by an intramuscular or subcutaneous injection, with a pre-filled syringe. In the case of the measles vaccine, we found three drugs of extemporaneous preparation that are presented as lyophilized powder in vial and vehicle in a pre-filled syringe. They are produced from different live or attenuated viruses so they are combined vaccines.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[vacunas]]></kwd>
<kwd lng="es"><![CDATA[sarampión]]></kwd>
<kwd lng="es"><![CDATA[formulación]]></kwd>
<kwd lng="es"><![CDATA[movimiento antivacuna]]></kwd>
<kwd lng="en"><![CDATA[vaccines]]></kwd>
<kwd lng="en"><![CDATA[measles]]></kwd>
<kwd lng="en"><![CDATA[formulation]]></kwd>
<kwd lng="en"><![CDATA[anti-vaccine movement]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[World Health Organization]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<source><![CDATA[Asociación Española de Vacunología: Vacuna y más]]></source>
<year>2020</year>
<publisher-name><![CDATA[Red de Seguridad Vacunal de la OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<source><![CDATA[Centro de Información Online de Medicamentos de la AEMPS]]></source>
<year></year>
<publisher-name><![CDATA[Agencia Española del Medicamento y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eve-Crager]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving Global Access to New Vaccines: Intellectual Property]]></article-title>
<source><![CDATA[Am J Public Health]]></source>
<year>2014</year>
<volume>104</volume>
<page-range>85-91</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Santana]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zumalacárregui]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Quintana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Furrazola]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estrategias de obtención de proteínas recombinantes en Escherichia coli]]></article-title>
<source><![CDATA[Vacci Monitor]]></source>
<year>2013</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>30-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Guideline on adjuvants in vaccine for human use]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matzinger]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolerance, danger, and the extended family]]></article-title>
<source><![CDATA[Ann Rev Immunol]]></source>
<year>1994</year>
<volume>12</volume>
<page-range>991</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>Institute for Vaccine Safety</collab>
<article-title xml:lang=""><![CDATA[Vaccine Excipients per 0.5 mL dose]]></article-title>
<source><![CDATA[Johns Hopkins Bloomberg School of Public Health]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reig]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[La liofilización en el mercado global farmacéutico: proceso y necesidades tecnológicas]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baheti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bansal]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Excipients used in lyophilization of small molecules]]></article-title>
<source><![CDATA[J Excipients and Food Chem]]></source>
<year>2010</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-54</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leslie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Israeli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lighthart]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Crowe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Crowe]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trehalose and sucrose protect both membranes and proteins]]></article-title>
<source><![CDATA[Appl Environ Microbiol]]></source>
<year>1995</year>
<volume>61</volume>
<page-range>3592-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez-García]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Borràs-López]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[7ª Monografía de la Sociedad Española de Epidemiología: El sarampión]]></source>
<year>2008</year>
<edition>1ª</edition>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Gráficas Enar, S.A.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sarampión]]></article-title>
<source><![CDATA[Webconsultas. Revista de salud y bienestar]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wakefield]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Murch]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Anthony]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Linnell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Casson]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Malik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ileal-lymphoid-nodular hiperplasia, non-specific colitis, and pervasive developmental disorder in children]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>1998</year>
<volume>351</volume>
<page-range>637-41</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>Instituto Finlay. Centro de Investigación-Producción de Vacunas y Sueros</collab>
<source><![CDATA[Autismo y vacunas pediátricas]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
